ERBB2 and breast cancer: This result is of special interest since in BALB-neuT mice anti-neu vaccination affords a major and persistent protection against incipient mammary tumors whereas it is no longer able to extend the survival time of mice if started when mice display multiple invasive microscopic carcinomas (week 16) [22].